Follow The Filings

BGLC BioNexus Gene Lab

BioNexus Gene Lab earnings company data as of 4:48 AM ET 10/23

History

2 periods, newest first. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 13 Nov EPS — — —
Rev — — —
FY2026 Q2 14 Aug EPS — 0.12 —
Rev — — —

Insider trades

Open-market buys and sales by BGLC's executives, directors and 10% owners in the last 12 months, from their Form 4s

All BGLC insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales

No open-market buys or sales on file.

Also filed in the last 12 months, not counted as buying or selling: 5 stock grants.

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
SCHEDULE 13G —
8-K 1.01,3.02,7.01,9.01
SCHEDULE 13D —
10-Q FORM 10-Q
8-K 8.01,9.01
8-K 8.01,9.01
10-Q FORM 10-Q
10-K FORM 10-K
8-K 7.01,8.01,9.01
8-K 8.01,9.01
8-K 8.01,9.01
8-K 5.07
8-K 8.01
DEF 14A
8-K 1.01,3.02,7.01,9.01
10-Q FORM 10-Q
8-K 1.01,7.01,9.01
8-K 1.01,3.02,7.01,9.01
8-K 7.01,9.01
10-Q FORM 10-Q
8-K 7.01,9.01
8-K 5.02,9.01
10-Q FORM 10-Q
8-K 3.01,7.01,9.01
10-K/A FORM 10-K/A

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.